BackTorrent Pharmaceuticals Limited Overview

Torrent Pharmaceuticals Limited EBIT

Latest ebit for TORNTPHARM.NS: $37B, below the sector sector average of $2.3T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$10.57B
↑ 25.98% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$37.33B
↑ 20.37% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Torrent Pharmaceuticals Limited (TORNTPHARM.NS) FAQ

The latest EBIT for TORNTPHARM.NS is $37B as of September 2026. That compares with $31B in the prior-year period — up 20.4% year over year. That is below the sector sector average of $2.3T. Investors often review this figure alongside Torrent Pharmaceuticals Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, TORNTPHARM.NS's EBIT moved from $31B to $37B — a 20.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Torrent Pharmaceuticals Limited's operating scale or balance-sheet position.

Against its sector companies, TORNTPHARM.NS currently prints $37B for EBIT, while the sector average sits near $2.3T. That is roughly 98.4% below the sector mean. Large gaps often invite a closer look at Torrent Pharmaceuticals Limited's growth, margins, and balance sheet.

A EBIT figure of $37B for TORNTPHARM.NS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.3T. Explore the charts below for those layers of context.

After noting TORNTPHARM.NS's EBIT ($37B), review year-over-year change from $31B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers